NAD+, SS-31 and AICAR are all studied in relation to cellular energy metabolism and mitochondrial function, but they work in different ways. NAD+ is an essential coenzyme that several classes of enzyme depend on. SS-31 is a mitochondria-targeted peptide that associates with the inner-membrane phospholipid cardiolipin. AICAR is a small molecule that activates the cellular energy sensor AMP-activated protein kinase (AMPK).
The research on these compounds therefore covers different parts of cellular energy biology, from coenzyme availability through mitochondrial membrane function to metabolic signaling. Every finding below is identified as in vitro or animal. Nothing here should be read as an outcome an individual should expect. These are research compounds.
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every cell. It cycles between an oxidized form (NAD+) and a reduced form (NADH) to carry electrons through the reactions of central metabolism, including glycolysis and the mitochondrial electron transport chain.
Beyond this redox role, two enzyme families also consume NAD+ as a substrate, which connects the coenzyme to broader cellular signaling. The sirtuins are NAD+-dependent deacylases that remove acetyl and related groups from target proteins, which links their activity to how much NAD+ is available. The poly(ADP-ribose) polymerases (PARPs) consume NAD+ while attaching ADP-ribose units to proteins during processes such as DNA repair. Because sirtuins and PARPs both consume NAD+, changes in the cellular NAD+ pool can affect processes spanning metabolism, protein modification and genome maintenance.
Covarrubias and colleagues reviewed the NAD+ literature across cell and animal models. They report that cellular NAD+ levels shift with age, and so does the balance between its synthesis and consumption [1]. That pattern contributes to the interest in NAD+ in metabolic and mitochondrial research. These are cell and animal findings, summarized in a mechanistic review.
SS-31, also referred to as elamipretide, is a synthetic mitochondria-targeted tetrapeptide, meaning it is four amino acids long. It concentrates at the inner mitochondrial membrane. Its defining feature is an association with cardiolipin, a phospholipid found almost exclusively in that membrane and important for organizing the protein complexes of the electron transport chain (ETC).
Working with isolated mitochondria and an animal model of ischemia, Birk and colleagues reported that SS-31 binds cardiolipin and helps preserve mitochondrial structure and function during ischemia. The peptide was associated with preserved cristae structure, improved ATP recovery and reduced mitochondrial damage under ischemic conditions [2]. Szeto set out the broader mechanistic case and described SS-31 as a cardiolipin-protective compound [3]. Szeto also proposed that its interaction with cardiolipin helps maintain the integrity of the cristae membranes, where oxidative phosphorylation occurs, and that this supports mitochondrial bioenergetics [3].
Unlike NAD+, which participates in metabolic reactions and enzyme signaling, SS-31 is studied primarily through its interaction with a structural component of the mitochondrial membrane. These are in vitro and animal findings.
AICAR, short for 5-aminoimidazole-4-carboxamide ribonucleoside, acts through the pathway a cell uses to sense its own energy state. Inside the cell it is converted to a nucleotide called ZMP, which mimics AMP, the molecule that accumulates when a cell's energy charge falls. Through that mimicry AICAR activates AMP-activated protein kinase (AMPK), a cellular energy sensor that shifts metabolism toward ATP-generating pathways when activated.
The foundational cellular evidence came from Corton and colleagues, who showed in isolated liver cells (hepatocytes) that AICAR could activate AMPK within intact cells [4]. That work established AICAR as a useful experimental tool for studying the pathway.
AMPK signaling also connects with NAD+-dependent pathways. A recent review by Chen and colleagues summarizes how AMPK, the NAD+-dependent sirtuin SIRT1, and the transcriptional coactivator PGC-1α operate as a connected signaling module. The review describes that module as regulating energy homeostasis and mitochondrial biogenesis across cell and animal models [5]. This provides a mechanistic link between the AICAR and NAD+ research discussed here, but it does not imply that the two act through the same pathway. These are in vitro and animal findings.
The evidence for these three compounds differs in both type and maturity. The NAD+ literature is extensive at the level of biochemistry and cell biology. But linking a change in the shared NAD+ pool to a specific biological effect is difficult, because NAD+ is used by many different enzymes and pathways.
The SS-31 mechanism is supported by studies of cardiolipin interaction and mitochondrial function, together with animal work. Even so, effects observed at the organelle level do not necessarily translate directly to whole-organism outcomes. AICAR is a well-established laboratory activator of AMPK, but it is not fully selective. Its intracellular metabolite ZMP can also produce AMPK-independent effects, which has to be taken into account when interpreting experiments that use AICAR. None of these findings can be used to predict human outcomes.
NAD+, SS-31 and AICAR are all used to investigate cellular energy biology, but each addresses a different part of that biology. NAD+ is a shared coenzyme whose availability links central metabolism to the sirtuin and PARP enzyme families. SS-31 is a mitochondria-targeted peptide studied for its interaction with cardiolipin and for its association with mitochondrial membrane and electron transport function. AICAR is a pharmacological activator of the AMPK energy-sensing pathway. There is some interaction between these systems, particularly between AMPK and NAD+-dependent signaling, but the compounds themselves should not be treated as mechanistically equivalent. The evidence discussed here describes experimental mechanisms investigated in vitro or in animals. It should not be taken as evidence of an expected effect in an individual. These compounds are discussed for research purposes only.
References
Growth hormone secretagogues (GHS) are molecules studied for their ability to make the pituitary gland release growth hormone (GH). Research so far has found that these molecules can reach the same end point by different routes or pathways. This article compar
GHK-Cu, Matrixyl, PAL-GHK and Snap-8 all appear in dermal research, but they do not all act through the same biological pathway. This article discusses GHK-Cu, Matrixyl and PAL-GHK in relation to collagen and extracellular matrix (ECM) biology. Snap-8 is studi
The IGF-1 family includes several research compounds. Each one acts within the insulin-like growth factor 1 (IGF-1) signaling system, or is derived from it. Growth hormone secretagogues work upstream at the pituitary to raise growth hormone, but these compound
The myostatin pathway is one of the clearest biological systems involved in limiting skeletal muscle growth. GDF-8, Follistatin and ACE-031 each act at a different point in this pathway: GDF-8 provides the inhibitory signal, and Follistatin binds and neutraliz
Vesilute is a trade name for the dipeptide Glu-Asp. The one indexed animal study found no difference from its amino acids on the three endpoints it measured.
Thymulin is a zinc-dependent thymic nonapeptide. Its human trials date from the 1980s, it is approved nowhere, and its newest evidence is preclinical.
